Teva gets expanded approval on MS drug

Teva Pharmaceutical Industries Ltd. said today that the U.S. Food and Drug Administration approved an expanded indication for Copaxone to treat patients who have experienced a first clinical episode and have magnetic resonance imaging features consistent with multiple sclerosis.

Copyright PHILY -
Contact Us